VERU addendum—The steep selloff today may have been triggered by the lack of incremental weight loss for patients in the 3mg and 6mg Enobosarm + Wegovy arms compared to the Wegovy control arm. However, Enobosarm is not intended to increase weight loss when used as an addend to GLP-1, but rather is intended to reduce the amount of muscle loss for a given amount of overall weight loss. So, today’s price action seems counter-intuitive. (No position.)
Market Data 
Markets 
